Surgery Partners (SGRY) Cash & Equivalents (2013 - 2026)

Surgery Partners has disclosed Cash & Equivalents across 14 years of filings, most recently posting $182.3 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $182.3 million, down 20.5% year-over-year; the trailing twelve-month figure through Mar 2026 was $182.3 million (down 20.5% YoY), and the FY2025 annual result was $239.9 million, down 10.98% from the prior year.
• Cash & Equivalents came in at $182.3 million for Q1 2026 at Surgery Partners, down from $239.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $378.9 million in Q1 2022 to a low of $154.8 million in Q3 2022.
• The 5-year median for Cash & Equivalents is $227.4 million (2022), against an average of $229.0 million.
• Across the five-year window, Cash & Equivalents slumped 53.15% in 2022 and soared 52.45% in 2023, its largest moves.
• Surgery Partners' Cash & Equivalents stood at $282.9 million in 2022, then slumped by 30.75% to $195.9 million in 2023, then jumped by 37.57% to $269.5 million in 2024, then dropped by 10.98% to $239.9 million in 2025, then slipped by 24.01% to $182.3 million in 2026.
• The last three Cash & Equivalents figures came in at $182.3 million (Q1 2026), $239.9 million (Q4 2025), and $203.4 million (Q3 2025), per Business Quant data.